<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lise Boey</style></author><author><style face="normal" font="default" size="100%">Eline Bosmans</style></author><author><style face="normal" font="default" size="100%">Liane Braz Ferreira</style></author><author><style face="normal" font="default" size="100%">Nathalie Heyvaert</style></author><author><style face="normal" font="default" size="100%">Melissa Nelen</style></author><author><style face="normal" font="default" size="100%">Lisa Smans</style></author><author><style face="normal" font="default" size="100%">Hanne Tuerlinckx</style></author><author><style face="normal" font="default" size="100%">Vandermeulen, Corinne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mathieu Roelants</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Kathleen Claes</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Derdelinckx, Inge</style></author><author><style face="normal" font="default" size="100%">Wim Janssens</style></author><author><style face="normal" font="default" size="100%">Mathieu, Chantal</style></author><author><style face="normal" font="default" size="100%">Johan Van Cleemput</style></author><author><style face="normal" font="default" size="100%">Robin Vos</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients.</style></title><secondary-title><style face="normal" font="default" size="100%">Vaccines (Basel)</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Jan 04</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Patients with chronic diseases are at increased risk of complications following infection. It remains, however, unknown to what extend they are protected against vaccine-preventable diseases. We assessed seroprevalence of antibodies against diphtheria, tetanus and pertussis to evaluate whether current vaccination programs in Belgium are adequate. Antibody titers were assessed with a bead-based multiplex assay in serum of 1052 adults with chronic diseases. We included patients with diabetes mellitus type 1 (DM1) ( = 172), DM2 ( = 77), chronic kidney disease ( = 130), chronic obstructive pulmonary disease (COPD) ( = 170), heart failure ( = 77), HIV ( = 196) and solid organ transplant (SOT) recipients ( = 230). Factors associated with seroprevalence were analysed with multiple logistic regression. We found seroprotective titers in 29% for diphtheria (≥0.1 IU/mL), in 83% for tetanus (≥0.1 IU/mL) and 22% had antibodies against pertussis (≥5 IU/mL). Seroprotection rates were higher ( &amp;lt; 0.001) when vaccinated within the last ten years. Furthermore, diphtheria seroprotection decreased with age ( &amp;lt; 0.001). Tetanus seroprotection was less reached in women ( &amp;lt; 0.001) and older age groups ( &amp;lt; 0.001). For pertussis, women had more often a titer suggestive of a recent infection or vaccination (≥100 IU/mL, &amp;lt; 0.01). We conclude that except for tetanus, the vast majority of at-risk patients remains susceptible to vaccine-preventable diseases such as diphtheria and pertussis.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>